Published in Mov Disord on September 15, 2007
Unusual complications of deep brain stimulation. Neurosurg Rev (2014) 0.77
Thrombosed traumatic aneurysm of the occipital artery: a case report and review of the literature. J Med Case Rep (2012) 0.75
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Ischemic bilateral hippocampal dysfunction during transient global amnesia. Neurology (2007) 2.10
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci (2011) 1.76
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 1.76
Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain (2011) 1.75
Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci (2003) 1.66
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol (2010) 1.50
Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry (2007) 1.48
Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol (2007) 1.47
Cyclic vomiting syndrome, migraine, and epilepsy: a common underlying disorder? Headache (2003) 1.47
Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache (2006) 1.45
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol (2002) 1.36
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci (2003) 1.31
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry (2008) 1.31
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord (2005) 1.26
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord (2011) 1.25
Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol (2012) 1.20
Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci (2009) 1.16
Plasticity and repair in the post-ischemic brain. Neuropharmacology (2008) 1.16
Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory. Behav Brain Res (2008) 1.15
Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons. J Physiol (2003) 1.15
Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol (2004) 1.15
Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci (2011) 1.14
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One (2010) 1.13
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord (2007) 1.13
A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology (2004) 1.13
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci (2004) 1.13
Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology (2002) 1.13
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology (2002) 1.10
Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol (2009) 1.09
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology (2007) 1.07
Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci (2008) 1.07
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci (2004) 1.06
Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci (2003) 1.06
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis (2012) 1.05
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain (2010) 1.05
Cortical spreading depression as a target for anti-migraine agents. J Headache Pain (2013) 1.03
Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. Eur J Neurosci (2002) 1.02
Recurrent hypothermia with hyperhidrosis in two siblings: familial Shapiro syndrome variant. J Neurol (2011) 1.01
Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain (2007) 1.00
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology (2012) 1.00
Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache (2009) 1.00
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology (2005) 1.00
Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci (2002) 0.99
Occipital arteriovenous malformations and migraine. Cephalalgia (2011) 0.97
Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia (2004) 0.97
Removing pathogenic memories: a neurobiology of psychotherapy. Mol Neurobiol (2005) 0.97
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging (2011) 0.97
Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci (2010) 0.97
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain (2012) 0.96
Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol Dis (2013) 0.96
Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis (2010) 0.96
c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model. J Biol Chem (2011) 0.96
NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke (2006) 0.95
Inhibition of persistent sodium current fraction and voltage-gated L-type calcium current by propofol in cortical neurons: implications for its antiepileptic activity. Epilepsia (2005) 0.95
Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans (2010) 0.95
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis (2005) 0.94
Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. J Headache Pain (2014) 0.94
Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett (2008) 0.94
Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia (2009) 0.94
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord (2013) 0.94
Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol (2007) 0.94
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis (2010) 0.93
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain (2004) 0.93
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem (2003) 0.93
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci (2002) 0.93
Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry (2005) 0.92
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain (2002) 0.92
Application of the ICHD-II criteria to the diagnosis of primary chronic headaches via a computerized structured record. Headache (2007) 0.92
Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. Mov Disord (2007) 0.92
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke (2006) 0.91
Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep (2007) 0.91
Medication-overuse headache: pathophysiological insights. J Headache Pain (2005) 0.91
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol (2009) 0.90
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis (2007) 0.90
Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med (2007) 0.90
Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke (2004) 0.89
Decreased contralateral putamen [I]FP-CIT SPECT uptake in hyperglycemic hemichorea-hemiballismus. Eur Neurol (2011) 0.89
Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology (2006) 0.89
A case of vertebrobasilar stroke during oxygen-ozone therapy. J Stroke Cerebrovasc Dis (2007) 0.89
Mortalin inhibition in experimental Parkinson's disease. Mov Disord (2011) 0.88
The brain cytoplasmic RNA BC1 regulates dopamine D2 receptor-mediated transmission in the striatum. J Neurosci (2007) 0.88
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. J Neurosci (2012) 0.87